Gyros Protein Technologies introduces Gyrolab Generic Anti-AAV Kit to support gene therapy development Post author: Post published:June 17, 2024 Post category:uncategorized Ready-to-use kit enables detection of binding antibodies against AAV vectors without the need for serotype-specific assays. You Might Also Like Language service cutbacks raise fear of medical errors, misdiagnoses, deaths May 29, 2025 Flu viruses can use a second entry pathway to infect cells July 18, 2024 Researchers reveal mechanisms of how CDK12 alterations drive prostate cancer development October 4, 2024
Researchers reveal mechanisms of how CDK12 alterations drive prostate cancer development October 4, 2024